Tag: MNPR

  • Monopar Therapeutics Inc. (MNPR) Stock Rocketing Higher in Premarket. What’s Going on.

    Monopar Therapeutics Inc. (MNPR) Stock Rocketing Higher in Premarket. What’s Going on.

    Monopar Therapeutics Inc. (MNPR) is a late-stage biotherapeutics company engaged in the development of exclusive therapeutics used to extend the life span of cancer patients. The company’s product pipeline includes consists of Validive for the reduction of -induced oral mucositis induced by chemoradiotherapy in oropharyngeal cancer patients. Camsirubicin is another candidate for treating advanced soft tissue sarcoma, MNPR-101, and MNPR-202 for different cancer types and COVID-19.

    The price of MNPR stock during the regular trading on February 17, 2022, was $2.98 with a gain of 2.52%. At last check in the premarket on February 18, 2022, the stock rocketed by 20.6%.

    MNPR: Events and Happenings

    On February 15, 2022, MNPR updated about its pipeline projects and expected 2022 highlights. Some of the key updates are mentioned below.

    • Validive Phase 2/3 VOICE clinical studies is actively recruiting.
    • Camsirubicin Phase 1 dose-escalation trial is actively Recruiting.

    On January 07, 2022, MNPR reported its Executive management’s participation at the H.C. Wainwright BioConnect Conference on January 10, 2022. On December 08, 2021, MNPR announced optimistic recommendations regarding camsirubicin from the safety review committee. The committee recommended stepping up to the second dose stage in its Phase 1 trials. The committee reviewed the safety data in the initial dose cohort.

    MNPR: Key Financials

    On November 12, 2021, MNPR released its financial results for the third fiscal quarter 2021 ended September 30, 2021. Some of the key highlights are mentioned below.

    EPS

    Basic and diluted net loss per share in Q3 2021 was $2.45 million or $0.20 against $1.63 million or $0.15 in the same period of 2020. The EPS of the company decreased over the yearly period. The company beat the analysts’ estimated EPS by $0.01.

    On October 27, 2021, MNPR informed the dosage of preliminary patients in Phase 1b clinical trials of camsirubicin.

    Conclusion

    MNPR stock is 38% down the six months and 64% down the past year. The recent premarket stock soaring is because of uncertain factors as the company did not report any SEC filing, official news, or recent event in the company’s calendar. Meanwhile, the analysts estimated the fourth quarter’s EPS to be in the range of -$0.19.

     

  • Early Morning Vibes: 4 Growth Stocks to Watch Right Now

    Early Morning Vibes: 4 Growth Stocks to Watch Right Now

    On January 28, American stock markets closed in the green zone. The S&P 500 index rose 0.98% to 3787 points, the NASDAQ gained 0.50%, the Dow Jones rose 0.99%. The rebound after the sale on the eve was caused by technical factors, as well as the publication of mostly positive macro statistics. All 11 sectors finished the session in positive territory. The finance sector showed outstripping growth by 1.92% due to the increase in the quotations of shares of payment systems and banks.

    Company news

    Comcast (CMCSA: + 6.6%) posted strong quarterly results thanks to continued strong demand for home internet. Some amusement parks have reached break-even points.

    MasterCard (MA: + 2.8%) quarterly EPS came in better than expected on a solid recovery in US earnings.

    Tesla’s revenue (TSLA: -3.3%) beat consensus expectations, but gross margin declined. The company’s forecast for the supply of electric vehicles in 2021 was weaker than analysts had predicted.

    Today world stock markets are showing negative dynamics. In the real economy, the news background remains calm, however, short squeezes in individual stocks continue to attract attention, causing concern among professional market participants.

    Risk appetite is highly variable. On the one hand, quarterly corporate results are mostly stronger than expected. Many support factors, including fiscal and monetary policy, an improvement in the epidemiological situation in the world, the emergence of new vaccines, remain relevant. In particular, Novavax today published positive test results for its drug.

    At the same time, hedge funds lock in positions to cover losses on short positions. In addition, market participants are avoiding risk by observing excess volatility and cautiously comparing the current situation to the stock market bubble before the dotcom crash. A significant risk is the spread of mutations in the coronavirus. The Novavax vaccine is only 49% effective against its South African strain. Thus, the market equilibrium appears to be fragile, so investors should be careful.

    The Freedom Finance Sentiment Index dropped to 68 out of 100. The indicator reflects the hope of market participants for a recovery in the global economy in 2021. Concerns about the negative impact of the coronavirus pandemic are gradually diminishing thanks to the prospects for mass vaccinations.

    Technical picture

    Technically, the S&P 500 is prone to an upward movement in the medium term. Nevertheless, the short-term correction may continue, as the MACD indicator is in negative territory. Significant support is located at 3710 points, where the 50-day moving average lies. The medium-term outlook for the S&P 500 will worsen if it falls below 3630 points.

    Today Top Movers‎

    LM Funding America Inc (LMFA), a specialty finance company, soared about 86.67% ‎at $2.79 in pre-market ‎trading Friday.‎‎ The company declared the closing of a $103.5 million upsized initial public offering.

    ‎Genius Brands International Inc (GNUS) share price jumped 16.75% to $2.30 during early morning ‎trading session on ‎Friday.‎‎

    Monopar Therapeutics Inc (MNPR) stock ascended 9.17% at $9.29 in the pre-‎market trading today.‎‎

    Sundial Growers Inc (SNDL) gained over 14.34% at $0.94 in pre-market ‎trading on Friday.‎‎

    Top Upgrades & Downgrades

    Wells Fargo turned bullish on Alliance Data Systems Corporation (ADS), upgrading the stock to “Equal-Weight” and assigning a $75 price target, representing a potential upside of 5.94% from Thursday’s close.

    SLM Corporation (SLM) has won the favor of RBC Capital’s equity research team. The firm upgraded the shares from Sector Perform to Outperform and moved their price target to $20, suggesting a 43.57% additional upside for the stock.

    Capri Holdings Limited (CPRI) received an upgrade from analysts at Baird, who also set their one-year price target on the stock to $58. They changed their rating on CPRI to Outperform from Neutral in a recently issued research note.

    Earlier Friday Jefferies reduced its rating on Golar LNG Partners LP (GMLP) stock to Hold from Buy and assigned the price target to $3.5. With shares trading at around $3.42, the Wall Street firm thinks Golar LNG Partners LP’s stock could add 2.34%.

    Jefferies analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Safe Bulkers Inc. (SB) has been changed to Hold from Buy and the new price target is set at $1.8.

    Analysts at Morgan Stanley downgraded DXC Technology Co (DXC)’s stock to Equal Weight from Overweight Friday.

    Latest Insider Activity

    The Macerich Company (MAC) 10% Owner ONTARIO TEACHERS PENSION PLAN announced the sale of shares taking place on Jan 27 at $20.25 for some 24,562,964 shares. The total came to more than $497.37 million.

    Houston American Energy Corp. (HUSA) Director SCHOONOVER JAMES A sold on Jan 26 a total of 142,976 shares at $2.63 on average. The insider’s sale generated proceeds of almost $43960.

    Jefferies Financial Group Inc. (JEF) 10% Owner Jefferies Financial Group Inc. declared the purchase of shares taking place on Jan 12 at $10.00 for some 250,000 shares. The transaction amount was around $2.5 million.

    Alcoa Corporation (AA) Director Nevels James E bought on Jan 27 a total of 32,336 shares at $17.50 on average. The purchase cost the insider an estimated $7,000.

    Important Earnings

    Top US earnings releases scheduled for today include Telefonaktiebolaget LM Ericsson (publ) (NASDAQ:ERIC). It will announce its Dec 2020 financial results. The company is expected to report earnings of $0.21 per share from revenues of $7.75B in the three-month period.

    Analysts expect Synchrony Financial (NYSE:SYF) to report a net income (adjusted) of $0.91 per share, when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $3.55B.

    Chevron Corporation (CVX), due to announce earnings before the market opens today, is expected to report earnings of $0.07 per share from revenues of $26.2B recently concluded three-month period.